This brand name is authorized in Canada
The drug CABENUVA contains a combination of these active pharmaceutical ingredients (APIs):
|
1
Cabotegravir
UNII 3L12PT535M - CABOTEGRAVIR SODIUM
|
|
Cabotegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. |
|
2
Rilpivirine
UNII FI96A8X663 - RILPIVIRINE
|
|
Rilpivirine is a diarylpyrimidine NNRTI of HIV-1. Rilpivirine activity is mediated by non-competitive inhibition of HIV-1 reverse transcriptase (RT). Rilpivirine does not inhibit the human cellular DNA polymerases α, β and γ. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J05AR | Antivirals for treatment of HIV infections, combinations | J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: CA | Health Products and Food Branch | Identifier(s): 02497220, 02497247 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
